The latest biotech news

News and Trends 22 Sep 2022

Emyria starts program with neuroscience drug discovery CRO

Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA analogs from their proprietary library using PsychoGenic’s drug discovery platform, SmartCube. SmartCube extracts and analyzes behavioral and […]

September 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

A U.S.-based biotech yesterday (September 21) reported additional biomarker results for a treatment of type 2 diabetes (T2D) from a phase 1 study. Glyscend Therapeutics, has been looking at orally administered drug GLY-200, which is a gut-restricted therapeutic. The company also received clearance from the U.S. Food and Drug Administration (FDA) on an Investigational New […]

September 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

National Hemophilia Foundation launches research fund

The National Hemophilia Foundation (NHF) in the U.S. has announced the launch of Pathway to Cures (P2C), a new venture philanthropy investment fund focused on creating transformational impact across all inheritable blood disorders. Investing alongside and partnering with traditional private capital funds and other industry organizations, P2C hopes to spur the development of inheritable blood […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Swiss scientists reduce resistance of dormant melanoma cells

Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen in a majority of patients, most of them will undergo relapse even after sometimes spectacular initial responses. These relapses are due to “dormant” persistent cells, […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Promising MND drug slows disease progression

Scientists in the U.K. believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care. Results from a phase 3 clinical trial showed significant physical benefits for patients after 12 months. Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) found that patients with a faulty SOD1 […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

New study shows how prostate cancer may start

Researchers at the University of East Anglia in the U.K. say they have made an important discovery about how prostate cancer may start to develop. A new study published in Molecular Oncology reveals that the prostate as a whole, including cells that appear normal, is different in men with prostate cancer. It suggests that tissue […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 21 Sep 2022

Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn

Chemical bioinformatics company, Adapsyn Bioscience Inc., and Evotec SE have entered into a strategic collaboration that will allow Evotec to have the opportunity to evaluate the small molecules developed by Adapsyn. Evotec will look at the molecules as potential therapeutic candidates in proprietary and partnered drug discovery projects. The news was announced today (September 21) […]

September 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Sep 2022

NodThera reveals positive results for inflammasome inhibitors

Biotech company NodThera has announced positive phase 1 clinical readouts for its first and second clinical candidates, NT-0796 and NT-0249. A phase 1 study has been completed for NT-0796, confirming brain penetration with excellent pharmacokinetic (PK) and pharmacodynamic (PD) profiles and for NT-0249, dosing of the phase 1 single ascending dose cohorts has been completed, […]

September 21, 2022 - 2 minutesmins - By Jim Cornall

Optics11 Life receives €5 million in funding for drug development

News and Trends 21 Sep 2022

Quinten Health closes financing round to advance disease modeling platforms

A financing round to advance disease modeling platforms and virtual twins in real world has been closed by Quinten Health. The company that works in real-world data science, artificial intelligence (AI) and machine learning (ML) for precision care, made the announcement today (September 21). The round is part of the Quinten Group’s €14 million ($13.9 […]

September 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Sep 2022

FDA clears Cellenkos ALS drug for trial

Cellenkos, Inc., a clinical stage biotech company, has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a phase 1 safety study followed by a phase 1b randomized, double blind, placebo control trial of CK0803, neurotrophic allogeneic Treg cells, in patients with amyotrophic lateral sclerosis […]

September 21, 2022 - 3 minutesmins - By Jim Cornall

ANINA Transforms Ugly veg into Artistic Ready Meal 2 002

News and Trends 21 Sep 2022

Anina – reshaping the future of food by upcycling rejected vegetables

Two industrial design students were so concerned by the huge amounts of perfectly good fresh produce being wasted, they spent two years working on a healthy solution. Esti Brantz and Meydan Levy noticed that fruit and veg was getting tossed in the trash due to cosmetic reasons such as size, shape, color differences, or […]

September 21, 2022 - 5 minutesmins - By Liza Laws

News and Trends 21 Sep 2022

Poolbeg to investigate melioidosis vaccine candidate

Poolbeg Pharma has signed an exclusive agreement with University College Dublin (UCD) through NovaUCD, the university’s knowledge transfer office, for a late preclinical stage vaccine candidate for melioidosis, a disease for which there is no current approved vaccine available.The vaccine candidate, which is being developed by Poolbeg Pharma as POLB 003, was invented following many […]

September 21, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Emyria starts program with neuroscience drug discovery CRO

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

National Hemophilia Foundation launches research fund

Swiss scientists reduce resistance of dormant melanoma cells

Promising MND drug slows disease progression

New study shows how prostate cancer may start

Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn

NodThera reveals positive results for inflammasome inhibitors

Quinten Health closes financing round to advance disease modeling platforms

FDA clears Cellenkos ALS drug for trial

Anina – reshaping the future of food by upcycling rejected vegetables

Poolbeg to investigate melioidosis vaccine candidate

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!